Johnson & Johnson wins FDA accelerated approval for Rybrevant Faspro in head and neck cancer

Bitget2026/11/05 23:51

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Johnson & Johnson received FDA accelerated approval for Rybrevant Faspro as a single-agent treatment for recurrent or metastatic head and neck cancer.
Eligible adults must have progressed on or after platinum-based chemotherapy and an anti-PD-(L)1 antibody; HPV-associated oropharyngeal cancer is excluded.
Continued approval may depend on confirmation of clinical benefit in the Phase 3 OrigAMI-5 trial.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Johnson & Johnson published the original content used to generate this news brief on November 05, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Johnson & Johnson wins FDA accelerated approval for Rybrevant Faspro in head and neck cancer

You may also like

Crypto prices